Home > Research > Publications & Outputs > Glucagon-like peptide-1 analogues enhance synap...

Research

Links

Text available via DOI:

Keywords

View graph of relations

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. / McClean, Paula L.; Gault, Victor A.; Harriott, Patrick et al.
In: European Journal of Pharmacology, Vol. 630, No. 1-3, 25.03.2010, p. 158-162.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

McClean, PL, Gault, VA, Harriott, P & Hölscher, C 2010, 'Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease', European Journal of Pharmacology, vol. 630, no. 1-3, pp. 158-162. https://doi.org/10.1016/j.ejphar.2009.12.023

APA

McClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010). Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. European Journal of Pharmacology, 630(1-3), 158-162. https://doi.org/10.1016/j.ejphar.2009.12.023

Vancouver

McClean PL, Gault VA, Harriott P, Hölscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. European Journal of Pharmacology. 2010 Mar 25;630(1-3):158-162. doi: 10.1016/j.ejphar.2009.12.023

Author

McClean, Paula L. ; Gault, Victor A. ; Harriott, Patrick et al. / Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain : a link between diabetes and Alzheimer's disease. In: European Journal of Pharmacology. 2010 ; Vol. 630, No. 1-3. pp. 158-162.

Bibtex

@article{2509a6c7c573439194e15b903167e689,
title = "Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease",
abstract = "Type 2 diabetes has been identified as a risk factor for patients with Alzheimer's disease. Insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process. One potential strategy to help prevent this is the normalisation of insulin signalling in the brain. Therefore, the present study was designed to test the effects of novel enzyme-resistant analogues of the insulin-releasing incretin hormone, glucagon-like peptide 1 (GLP-1). The effects of Liraglutide (Victoza) and other novel GLP-1 analogues were tested on synaptic plasticity (LTP) in area CA1 of the hippocampus. At a dose of 15nmol in 5microl i.c.v., Liraglutide (P",
keywords = "Alzheimer Disease, Animals, Brain, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Long-Term Potentiation, Male, Rats, Rats, Wistar, Synapses",
author = "McClean, {Paula L.} and Gault, {Victor A.} and Patrick Harriott and Christian H{\"o}lscher",
year = "2010",
month = mar,
day = "25",
doi = "10.1016/j.ejphar.2009.12.023",
language = "English",
volume = "630",
pages = "158--162",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain

T2 - a link between diabetes and Alzheimer's disease

AU - McClean, Paula L.

AU - Gault, Victor A.

AU - Harriott, Patrick

AU - Hölscher, Christian

PY - 2010/3/25

Y1 - 2010/3/25

N2 - Type 2 diabetes has been identified as a risk factor for patients with Alzheimer's disease. Insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process. One potential strategy to help prevent this is the normalisation of insulin signalling in the brain. Therefore, the present study was designed to test the effects of novel enzyme-resistant analogues of the insulin-releasing incretin hormone, glucagon-like peptide 1 (GLP-1). The effects of Liraglutide (Victoza) and other novel GLP-1 analogues were tested on synaptic plasticity (LTP) in area CA1 of the hippocampus. At a dose of 15nmol in 5microl i.c.v., Liraglutide (P

AB - Type 2 diabetes has been identified as a risk factor for patients with Alzheimer's disease. Insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process. One potential strategy to help prevent this is the normalisation of insulin signalling in the brain. Therefore, the present study was designed to test the effects of novel enzyme-resistant analogues of the insulin-releasing incretin hormone, glucagon-like peptide 1 (GLP-1). The effects of Liraglutide (Victoza) and other novel GLP-1 analogues were tested on synaptic plasticity (LTP) in area CA1 of the hippocampus. At a dose of 15nmol in 5microl i.c.v., Liraglutide (P

KW - Alzheimer Disease

KW - Animals

KW - Brain

KW - Diabetes Mellitus, Type 2

KW - Glucagon-Like Peptide 1

KW - Long-Term Potentiation

KW - Male

KW - Rats

KW - Rats, Wistar

KW - Synapses

U2 - 10.1016/j.ejphar.2009.12.023

DO - 10.1016/j.ejphar.2009.12.023

M3 - Journal article

C2 - 20035739

VL - 630

SP - 158

EP - 162

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -